Search results for "Viral Vaccines."

showing 6 items of 26 documents

Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pa…

2008

Exogenous introduction of particle-associated proteins of human cytomegalovirus (HCMV) into the major histocompatibility complex (MHC) class I presentation pathway by subviral dense bodies (DB) is an effective way to sensitize cells against CD8 T-cell (CTL) recognition and killing. Consequently, these particles have been proposed as a platform for vaccine development. We have developed a strategy to refine the antigenic composition of DB. For proof of principle, an HCMV recombinant (RV-VM3) was generated that encoded the immunodominant CTL determinant IE1TMY from the IE1 protein in fusion with the major constituent of DB, the tegument protein pp65. To generate RV-VM3, a bacterial artificial…

Recombinant Fusion ProteinsvirusesCytomegalovirusImmunodominanceMajor histocompatibility complexImmediate-Early Proteinslaw.inventionViral ProteinsAntigenlawVirologyMHC class IHumansAntigen PresentationbiologyHistocompatibility Antigens Class IVirionvirus diseasesViral VaccinesGenetic TherapyFusion proteinVirologyPeptide FragmentsCTL*Cytomegalovirus Infectionsbiology.proteinRecombinant DNACD8T-Lymphocytes CytotoxicJournal of General Virology
researchProduct

Rotavirus-Specific Cytotoxic T Lymphocytes Recognize Overlapping Epitopes in the Amino-Terminal Region of the VP7 Glycoprotein

1999

Abstract Rotavirus-specific cytotoxic T lymphocytes (CTL) play an important role in the resolution of rotavirus infection. The outer capsid glycoprotein, VP7, elicits a class I MHC-restricted CTL response. Vaccinia virus recombinants expressing the VP7 genes from simian rotavirus SA11 (serotype G3) and from the RF strain of bovine rotavirus (serotype G6) were used to analyze the CTL activity to this antigen in BALB/c (H-2 d ) and C57BL/6 (H-2 b ) mice neonatally infected with homologous and heterologous rotaviruses. A vaccinia virus recombinant expressing the first amino-terminal 88 amino acids of VP7 was constructed and used to search for cross-reactive CTL against this region of the prote…

RotavirusRecombinant Fusion ProteinsvirusesGenetic VectorsEpitopes T-LymphocyteGene ExpressionVaccinia virusBiologymedicine.disease_causeVirusEpitopeMicechemistry.chemical_compoundCapsidfluids and secretionsAntigenVirologyRotavirusmedicineAnimalsCytotoxic T cellAntigens ViralGlycoproteinschemistry.chemical_classificationMice Inbred BALB CVaccines SyntheticVaccinationH-2 Antigensvirus diseasesViral VaccinesVirologyMolecular biologyMice Inbred C57BLCTL*Animals NewbornchemistryCapsid ProteinsCattleVacciniaPeptidesGlycoproteinT-Lymphocytes CytotoxicVirology
researchProduct

Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles.

2005

Induction of high frequencies of specific T cells by vaccination requires prime-boost regimens. To reach optimal immune responses, it is necessary to use different vectors for priming and boosting as e.g. DNA vaccination followed by boosting with a recombinant viral vector. Here, we show that vaccines based on virus-like particles (VLP) displaying peptide epitopes are equally effective to induce CTL responses if used in a homologous or heterologous prime-boost setting. Strikingly, high frequencies (>20% of CD8(+) cells) of protective CTL could be induced and maintained by weekly injection of VLP. Thus, the use of VLP may avoid the requirement for complicated heterologous prime-boost regi…

T cellvirusesT-LymphocytesImmunologyT-cell vaccinationPriming (immunology)HeterologousEpitopes T-LymphocyteVaccinia virusBiologycomplex mixturesEpitopeViral vectorDNA vaccinationMicemedicineVaccines DNAVacciniaImmunology and AllergyAnimalsVaccinationVirionViral VaccinesVirologyHepatitis B Core AntigensCTL*medicine.anatomical_structureImmunologyCpG IslandsFemale
researchProduct

“MIATA”—Minimal Information about T Cell Assays

2009

Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.

T-LymphocytesT cellmedicine.medical_treatmentImmunologyHuman immunodeficiency virus (HIV)medicine.disease_causeT cell responseCancer VaccinesArticleMonitoring ImmunologicNeoplasmsmedicineHumansImmunology and AllergyIn patientImmunoassaybusiness.industryViral VaccineCancerViral VaccinesImmunotherapymedicine.diseaseVaccinationInfectious Diseasesmedicine.anatomical_structureVirus DiseasesPractice Guidelines as TopicImmunologyImmunotherapybusinessCancer Vaccines/immunology; Cancer Vaccines/therapeutic use; Humans; Immunoassay/standards; Immunotherapy; Monitoring Immunologic/standards; Neoplasms/therapy; Practice Guidelines as Topic/standards; T-Lymphocytes/immunology; Viral Vaccines/immunology; Viral Vaccines/therapeutic use; Virus Diseases/therapyImmunity
researchProduct

Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies?: A systematic review of controll…

2015

Severe gastroenteritis caused by canine parvovirus type 2 (CPV2) is a serious life-threatening disease in puppies less than 4-months of age. The emergence of new variants has provoked some concern about the cross-protection elicited by licensed canine parvovirus modified-live type 2 (CPV2) and type 2b (CPV2b) vaccines against the most recent subtype CPV2c. A systematic review was carried out to assess the efficacy of commercial vaccines. We conducted a literature search of Pub Med/MEDLINE from January 1990 to May 2014. This was supplemented by hand-searching of related citations and searches in Google/Google Scholar. Controlled clinical trials in which vaccinated puppies were challenged wit…

medicine.medical_specialtyBlindingParvovirus CanineCross ProtectionDiseaseMicrobiologyParvoviridae InfectionsDogsSpecies SpecificityInternal medicineAnimalsMedicineDog DiseasesViral sheddingGeneral Veterinarybiologybusiness.industryViral VaccineCanine parvovirusViral VaccinesGeneral Medicinebiology.organism_classificationVaccine efficacyGastroenteritisVirus SheddingClinical trialSystematic reviewImmunologybusinessVeterinary Microbiology
researchProduct

Evaluation of varicella vaccine effectiveness as public health tool for increasing scientific evidence and improving vaccination programs

2020

Brazil; Chickenpox Vaccine; Humans; Immunization Programs; Public Health; Vaccination; Chickenpox; Viral Vaccines.

medicine.medical_specialtyVaricella vaccineMEDLINESettore MED/42 - Igiene Generale E ApplicataScientific evidenceChickenpox VaccineChickenpoxmedicineHumansChickenpox VaccineViral Vaccines.Immunization Programsbusiness.industryImmunization ProgramPublic healthViral VaccineVaccinationlcsh:RJ1-570Viral Vaccineslcsh:PediatricsVaccinationFamily medicinePediatrics Perinatology and Child HealthPublic HealthbusinessBrazilHumanJornal de Pediatria
researchProduct